LNK-dependent negative control of JAK2 is crucial, as evidenced by the more rapid development of myeloproliferative neoplasm in LNK−/− mice expressing mutated JAK2V617F, and the description of myeloproliferative neoplasms associated with LNK mutations in humans [127,128]. Here, JAK2 is linked to myeloproliferative disorder.